Steven C. Gilman

Steven C. Gilman is a declared insider at 7 companies (board member); the most frequent names are Cubist Pharmaceuticals Inc, Vericel Corp and Akebia Therapeutics, Inc. Between 31 March 2008 and 26 June 2025, the trades on record add up to 163 filings.

The open-market side counts 4 purchases for €84k alongside 47 sales for €14.9M. Netting one side against the other leaves €14.8M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 16 share grants and 45 option exercises.

Half of the purchases are above €19k and half below. Of 4 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 30 June 2025: a share grant, in Scynexis Inc. The last insider purchase was made public on 23 December 2020, 2,130 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.